Regeneron Pharmaceuticals (REGN) Getting Somewhat Positive News Coverage, Study Shows
Media headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.7125179658143 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Cramer's lightning round: People might be bailing on Regeneron, but it's a buy (finance.yahoo.com)
- That Biotech M&A Wave? More like a Trickle (finance.yahoo.com)
- Keep an eye on Analysts Rating: Regeneron Pharmaceuticals, Inc. (REGN) – Wall Street Morning (wallstreetmorning.com)
- Cramer’s lightning round: People might be bailing on Regeneron, but it’s a buy – CNBC (cnbc.com)
Shares of Regeneron Pharmaceuticals (REGN) traded down $1.30 during trading hours on Friday, hitting $366.96. 830,679 shares of the stock traded hands, compared to its average volume of 782,990. The firm has a market cap of $39,430.00, a PE ratio of 33.33, a PEG ratio of 1.45 and a beta of 1.52. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a one year low of $340.09 and a one year high of $543.55.
REGN has been the subject of a number of analyst reports. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 31st. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a research report on Thursday, November 16th. Barclays downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Guggenheim reissued a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $471.11.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.